• The selection of candidates requires careful and systematic evaluation. • Monitoring will be coordinated by the pulmonologist and pharmacist to ensure safe and efficient use. • The benefit should be assessed 12 months after the start of treatment. The selection of candidates requires careful and systematic evaluation. Monitoring will be coordinated by the pulmonologist and pharmacist to ensure safe and efficient use. The benefit should be assessed 12 months after the start of treatment. Preventing exacerbations in chronic obstructive pulmonary disease (COPD) is a priority, as exacerbations accelerate progression, increase mortality, and impair quality of life. The use of biologics that act on specific inflammatory pathways through monoclonal antibodies in COPD offers a precision medicine strategy for high-risk patients who continue to experience frequent exacerbations despite optimal inhaled treatment. However, the use of these biologic therapies in COPD presents significant challenges, stemming from the clinical heterogeneity of the disease and the limited evidence available. Their indication and management must be personalized and precise, raising questions about how to implement a biologic therapy strategy in COPD in clinical practice. This clinical protocol focused on the use of biologic therapy in COPD sets out the objectives (“Why”), describes the selection of candidates (“In which patients”), the monitoring of response (“What should be measured”) and how to implement it in clinical practice (“How”) based on the available evidence and expert consensus.
M et al. (Sun,) studied this question.